Passage Bio Inc (PASG)

10:00 AM

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development - MyChesCo

10:00 AM

May 16, 2025

Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Tower Research Capital LLC TRC - Defense World

May 16, 2025

May 14, 2025

Fierce Biotech Layoff Tracker 2025: Allogene cuts 28% of staff; Kyverna trims workforce by 16% - Fierce Biotech

May 14, 2025

May 14, 2025

Passage Bio Reports Q1 2025 Financial Results - TipRanks

May 14, 2025

May 13, 2025

Wedbush Adjusts Price Target on Passage Bio to $3 From $4, Maintains Outperform Rating - marketscreener.com

May 13, 2025

May 13, 2025

Passage Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025

May 13, 2025

Passage Bio Q1 Income From Operations USD -16.459 Million - marketscreener.com

May 13, 2025

May 13, 2025

Passage Bio (PASG) Advances Phase 1/2 Trial for PBFT02, Eyes Fut - GuruFocus

May 13, 2025

May 13, 2025

Passage BIO, Inc. SEC 10-Q Report - TradingView

May 13, 2025

May 13, 2025

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights - GlobeNewswire

May 13, 2025

May 13, 2025

Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025

May 11, 2025

Passage Bio (PASG) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025

May 02, 2025

Layoff Tracker: BMS Closes Manufacturing Plant, Arvinas Axes One-Third of Staff - BioSpace

May 02, 2025

Apr 30, 2025

Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus

Apr 30, 2025

Apr 17, 2025

Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia

Apr 17, 2025

Apr 17, 2025

Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada

Apr 17, 2025

Apr 11, 2025

Passage Bio (NASDAQ:PASG) vs. Agenus (NASDAQ:AGEN) Critical Contrast - The AM Reporter

Apr 11, 2025

Apr 09, 2025

Analyzing Agenus (NASDAQ:AGEN) & Passage Bio (NASDAQ:PASG) - Defense World

Apr 09, 2025

Apr 07, 2025

PASG stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia

Apr 07, 2025

Apr 03, 2025

Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com

Apr 03, 2025

Apr 03, 2025

GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com

Apr 03, 2025

Mar 31, 2025

Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Passage Bio stock plunges to 52-week low of $0.35 - Investing.com

Mar 31, 2025

Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025

Mar 27, 2025

Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com

Mar 27, 2025

Mar 25, 2025

Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech

Mar 25, 2025

Mar 23, 2025

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo

Mar 23, 2025

Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025

Mar 16, 2025

Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo

Mar 16, 2025

Mar 13, 2025

Passage Bio stock plunges to 52-week low of $0.38 amid market challenges - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

Passage Bio stock plunges to 52-week low of $0.38 amid market challenges By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 13, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MyChesCo

Mar 13, 2025

Mar 09, 2025

Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program - MSN

Mar 09, 2025

Mar 08, 2025

Wedbush Comments on Passage Bio’s Q1 Earnings (NASDAQ:PASG) - Defense World

Mar 08, 2025